Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Crescent Biopharma, Inc./ 10-Q

Quarterly Report · 10-Q

Crescent Biopharma, Inc.

Quarterly Report

Filed Apr 29, 2026Accepted Apr 29, 2026, 4:06 PM EDTCIK 1253689Accession 0001628280-26-028362
View company →Permanent SEC source ↗
Share

Company context

GlycoMimetics is a late clinical-stage biotechnology company that was previously discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach was based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company’s goal was to develop transformative therapies for diseases with high unmet medical need. Learn more at www.glycomimetics.com.

Current securities

CBIONASDAQ · EQUITY · Current
Historical securities (1)
CBIONASDAQ · EQUITY · Historical · closed Oct 22, 2026

Recent company filings

  1. SCHEDULE 13G - filed by BlackRock, Inc. regarding CRESCENT BIOPHARMA, INC.Oct 27, 2026
  2. Other EventsOct 15, 2026
  3. 4 filingSep 18, 2026
  4. S-8 filingSep 18, 2026
  5. 144 filingSep 17, 2026

Registered securities in this filing

Crescent Biopharma, Inc. · 10-Q · Filed 2026-04-29

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Ordinary Shares, $0.001 par value per share

Symbol
CBIO
Exchange
NASDAQ
Classification
COMMON
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000162828026028362 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.